Watch two experts discuss the use of sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin in patients with type 1 diabetes (T1D).
Manon Khazrai, Dietitian and Diabetes Counsellor, considers why there is a need for adjunctive therapy and why SGLT inhibitors are a suitable option. Debbie Hicks, Nurse Consultant – Diabetes, provides insight into patient selection and mitigating the risk of diabetic ketoacidosis.
This activity is intended for specialist diabetes nurses, diabetes educators, dietitians and related specialists involved in the treatment of patients with T1D.
After watching this touchEXPERT OPINIONS, you should be able to:
- Describe the rationale for using sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin therapy in patients with type 1 diabetes (T1D)
- Recognize patients with T1D who are suitable for treatment with an SGLT inhibitor as an adjunct to insulin therapy
- Describe the risk factors for and key signs and symptoms of diabetic ketoacidosis (DKA), especially euglycemic DKA